UK Genetic Prostate Cancer Study: Epidemiology and Molecular Genetics Studies (UKGPCS)

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2012 by Institute of Cancer Research, United Kingdom
Sponsor:
Collaborators:
Cancer Research UK
Royal Marsden NHS Foundation Trust
Information provided by (Responsible Party):
Institute of Cancer Research, United Kingdom
ClinicalTrials.gov Identifier:
NCT01737242
First received: November 27, 2012
Last updated: November 29, 2012
Last verified: November 2012
  Purpose

The UKGPCS was set up to find genetic alterations which occur in patients who have prostate cancer.

A man's risk of developing prostate cancer increases if he has a first-degree relative (father or brother) who was diagnosed with prostate cancer at a young age. This is why we are looking for men who are affected at a young age or who have a family history of prostate cancer, since it is more probable that these prostate cancers are due to an inherited genetic cause rather than an environmental cause.

We also ask all men who come to the Royal Marsden Hospital to be treated for prostate cancer if they would like to take part in the study so that we can also look to see if we find genetic alterations in older men, and those who do not have a family history of prostate cancer.


Condition
Prostate Cancer

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: UK Genetic Prostate Cancer Study: Epidemiology and Molecular Genetics Studies

Resource links provided by NLM:


Further study details as provided by Institute of Cancer Research, United Kingdom:

Primary Outcome Measures:
  • To find genes which predispose to PrCa [ Time Frame: 2017 ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Whole blood, Prostate Tissue


Estimated Enrollment: 26000
Study Start Date: January 1993
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
  Show Detailed Description

  Eligibility

Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Any patients that meets the eligibility criteria and may be attending a hospital that have got ethical approval.

Criteria

Inclusion Criteria:

  • Man with PrCa at any age at diagnosis at Royal Marsden NHS Foundation Trust
  • Those outside the Royal Marsden NHS Foundation Trust with
  • PrCa at or below 60 years at diagnosis
  • PrCa in first-degree related pairs where one is ≤ 65 years at diagnosis
  • PrCa at any age in a cluster with 3 or more cases
  • Those able to understand the information sheet and give informed consent (language line is available for those who wish to have translation)
  • Any unaffected relatives of men who are already taking part in the study

Exclusion Criteria:

  • Man with PrCa who is too ill to take part
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01737242

Contacts
Contact: Rosalind A Eeles, FRCP FRCR 02086613642 rosalind.eeles@icr.ac.uk

Locations
United Kingdom
Institute of Cancer Research and Royal Marsden Hospital Recruiting
Sutton, Surrey, United Kingdom, SM2 5PT
Contact: Rosalind A Eeles, FRCP FRFR    02086613642    rosalind.eeles@icr.ac.uk   
Principal Investigator: Rosalind A Eeles, FRCP FRCR         
Sponsors and Collaborators
Institute of Cancer Research, United Kingdom
Cancer Research UK
Royal Marsden NHS Foundation Trust
Investigators
Principal Investigator: Rosalind A Eeles, FRCP FRCR Institute of Cancer Research and Royal Marsden Hospital
  More Information

Additional Information:
No publications provided

Responsible Party: Institute of Cancer Research, United Kingdom
ClinicalTrials.gov Identifier: NCT01737242     History of Changes
Other Study ID Numbers: 06/MRE02/4, CCR0848
Study First Received: November 27, 2012
Last Updated: November 29, 2012
Health Authority: United Kingdom: National Health Service

Keywords provided by Institute of Cancer Research, United Kingdom:
Prostate cancer
PSA

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases

ClinicalTrials.gov processed this record on September 18, 2014